Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

The securities to be sold were acquired upon the vesting of previously exercised stock options on 06/01/2012 through 05/11/2016

Date of Notice

09/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Andrea M.A. Pfeifer

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

AC Immune (NASDAQ:ACIU)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Plus de graphiques de la Bourse AC Immune

AC Immune (NASDAQ:ACIU)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025

Plus de graphiques de la Bourse AC Immune

Actualités AC Immune SA

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercredi 18 Décembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Vendredi 13 Décembre 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mardi 10 Décembre 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
Mardi 10 Décembre 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 14 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
Jeudi 14 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

AC Immune to Present at the Jefferies 2024 London Healthcare Conference
Mercredi 13 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mardi 5 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Mardi 5 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Vendredi 27 Septembre 2024 ( il y a 3 mois) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 19 Septembre 2024 ( il y a 3 mois) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercredi 18 Septembre 2024 ( il y a 3 mois) • Edgar (US Regulatory)

Plus d'articles sur AC Immune SA

BNP Paribas Issuance

Vontobel Financial Produ...

Morgan Stanley BV

BNP Paribas Issuance

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales